REG - hVIVO plc - Award of Share Options <Origin Href="QuoteRef">HVO.L</Origin>

hVIVOAnnouncement

16/01/2018 07:05

RNS Number : 9210B
hVIVO plc
16 January 2018
For immediate release 7.00am: 16 January 2018
HVIVO PLC
("hVIVO" or the "Company")
Award of Share Options 
hVIVO plc (AIM: HVO), a specialty biopharma company with discovery and clinical testing capabilities, announces that on 15 January 2018 it awarded the following options over ordinary shares of 5.0p each in the Company to Liam Eves:
Name
Position
Number of Share Options Awarded
Exercise price per Share
Date of Vesting
Percentage of issued ordinary share capital
Liam Eves
Executive Vice President,Humatics
136,364
5.0p
20December 2020
0.17%
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail:
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1
Details of the persons discharging managerial responsibilities/persons closely associated
a)
Name
Liam Eves
2
Reason for the notification
a)
Position/ status
Executive Vice President, Humatics - A person closely associated with Kym Denny, Chief Executive Officer of the Company
b)
Initial notification/ Amendment
Initial Notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
hVIVO plc
b)
Legal Entity Identifier
N/A
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Identification code
Options over Ordinary Shares of 5 pence each
ISIN:GB00B6ZM0X53
b)
Nature of the transaction
Award of options over Ordinary Shares in the Company
c)
Currency
GBP
d)
Price(s) and volume(s)
Director
Exercise Price (p)
Volume
Liam Eves
5.0
136,364
e)
Aggregated information
- Aggregated volume
- Exercise price
136,364 options over Ordinary Shares
5.0p
f)
Date of the transaction
15 January 2018
g)
Place of the transaction
London Stock Exchange, AIM
For further information please contact: 
hVIVO plc 
+44 207 756 1300 
Kym Denny (Chief Executive Officer) 

Graham Yeatman (Chief Financial & Business Officer) 



Media Enquiries
+1 919 710 9658
Susan Flood (Head of Marketing)



Numis Securities Limited
+44 207 260 1000 
Michael Meade / Freddie Barnfield (Nominated Adviser) 

James Black / Michael Burke (Corporate Broking) 



FTI Consulting 

Simon Conway / Victoria Foster Mitchell (UK)
+44 203 727 1000
John Capodanno / Evan Smith (US)
+1 212 850 5705
Notes to Editors: 
hVIVO plc ("hVIVO"), a specialty biopharma company with discovery and clinical testing capabilities, is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV and asthma exacerbation, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 50 clinical studies, inoculated over 2500 volunteers and has three first-in-class therapies currently in development with a growing pre-clinical pipeline.

This information is provided by RNS
The company news service from the London Stock Exchange
  END
DSHUVRVRWVAAAAR